David A. Siegel Ionis Pharmaceuticals Inc Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,332,411 shares of IONS stock, worth $47.2 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
1,332,411
Previous 1,287,111
3.52%
Holding current value
$47.2 Million
Previous $61.3 Million
12.99%
% of portfolio
0.13%
Previous 0.14%
Shares
29 transactions
Others Institutions Holding IONS
# of Institutions
402Shares Held
136MCall Options Held
862KPut Options Held
582K-
Vanguard Group Inc Valley Forge, PA15.1MShares$533 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$502 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$365 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.74MShares$309 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$279 Million5.32% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $5.02B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...